新着動画一覧

(PBH, CRWE, THLD) CRWENewswire Stocks In Action

Genomma Lab Internacional, S.A.B. de C.V. reported that it has submitted a non-binding proposal to acquire all of the outstanding shares of Prestige Brands Holdings Inc - PBH - common stock for $16.60 dollars per share in cash. Threshold Pharmaceuticals Inc - THLD - reported Positive Phase 2b Clinical Trial Results of TH-302 in Patients With Pancreatic Cancer. Crown Equity Holdings Inc - CRWE - reported that its subsidiary Crown Tele Services Inc. has entered into 2 letters of intent, one with BBN Solutions and the other with MVOX AG. CRWE also reported that it has launched two new online service companies: CRWE Real Estate and and CRWE Direct. ********************************* THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)

投稿者： karmastock
投稿日時：2012-02-22 04:36:32.0
視聴回数：674回
お気に入り登録：0
カテゴリ：ビジネス全般
タグ： PBH CRWE THLD Nasdaq:THLD NYSE:PBH OTC:CRWE

Threshold (THLD) Global Agreement with Merck KGaA

CRWENewswire, Stocks to Watch. Threshold Pharmaceuticals Inc - THLD - reported that a global agreement was signed with Merck KGaA, Darmstadt, Germany, to co-develop and commercialize TH-302, Threshold’s small molecule hypoxia-targeted drug. Threshold will receive an upfront payment of $25 million and could receive up to $35 million in additional development milestones during 2012. Threshold is also eligible to receive a $20 million milestone payment based on positive results from its randomized Phase 2 trial in pancreatic cancer. Total potential milestone payments are $525 million, comprised of $280 million in regulatory and development milestones and $245 million in sales-based milestones. *********************** THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://crwenewswire.com/disclaimer).

投稿者： karmastock
投稿日時：2012-02-05 05:10:20.0
視聴回数：394回
お気に入り登録：0
カテゴリ：ビジネス全般
タグ： merck Nasdaq:THLD THLD threshold

注目のキーワード（タグ）

会社概要｜ソリューション｜お問い合わせ｜スタッフ募集｜利用規約｜プライバシーポリシー